USRM US Stem Cell Inc (CE)

Bioheart, Inc. (BHRT.OB), a company focused on developing stem cell therapies for heart disease announced that they have entered into an agreement with Stemlogix, LLC, a veterinary regenerative medicine company, to provide additional cellular products and services to the veterinary market. Under the agreement, the companies will offer culture expanded bone marrow and adipose stem cells for use in animals with degenerative diseases or acute injuries. In addition, veterinary patients will have the option to bank their stem cells for future use. 

Bioheart's president and CEO, Mike Tomas said, "Bioheart is focused on commercializing cell therapies for cardiac patients and has many years' experience with a variety of different cell types. This partnership now allows us to utilize our existing laboratories and expertise to bring these products to the veterinary market."

The following services and products are currently available:

• Culture expanded bone marrow cells
• Culture expanded adipose cells
• Adipose stromal vascular cells
• Cryopreservation of cells

Jason Griffeth, Chief Operating Officer of Stemlogix said, "We are excited to expand our current regenerative therapies to include expanded and cryopreserved cellular therapies. We now have the ability to customize therapies to fit the exact needs of the patient by offering many different options. Our partnership with Bioheart allows us to offer even more regenerative medicine capability to our veterinary customers and their patients."

About Bioheart, Inc.

Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Our leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit http://www.bioheartinc.com.

About Stemlogix, LLC

Stemlogix is an innovative veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the best possible stem cell therapy to dogs, cats and horses at the point-of-care. Stemlogix provides veterinarians with the ability to isolate regenerative stem cells from a patient's own adipose (fat) tissue directly on-site within their own clinic or where a patient is located. Regenerative stem cells isolated from adipose tissue have been shown in studies to be effective in treating animal's suffering from osteoarthritis, joint diseases, tendon injuries, heart disorders, among other conditions. Stemlogix has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. For more information about veterinary regenerative medicine please visit www.stemlogix.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

CONTACT: Bioheart, Inc.
         Catherine Sulawsk-Guck
         Chief Operating Officer
         954-835-1500